Join
Live feed
·
PRReleasevia Quantisnow
MannKind Corporation logo

MannKind Announces FDA Approval of Furoscix ReadyFlow™, the First and Only Autoinjector Delivering IV-Equivalent Diuretic Therapy for the Treatment of Edema in Adults with Heart Failure or Chronic Kidney Disease

ByQuantisnow·Wall Street's wire, on your screen.
MNKD· MannKind Corporation
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track MNKD (MannKind Corporation) and more on Quantisnow.